Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Rapid detection of MYD88-L265P mutation by PCR-RFLP in B-cell lymphoproliferative disorders

Accumulating evidence suggests that chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and Waldenstrom’s macroglobulinemia (WM) have been associated with precursor conditions, termed CD5+ monoclonal B-cell lymphocytosis (MBL) for CLL,1 and monoclonal gammopathy of undetermined significance (MGUS) for MM2 and WM.3 However, the outcome for MGUS seems to be different, depending on the class of immunoglobulin expression. Immunoglobulin type G (IgG) and immunoglobulin type A (IgA) MGUS progress to MM, while immunoglobulin type M (IgM) MGUS is considered to be a distinct biological and clinical entity, and has been reported to progress most often to WM.3 However, the point at which MGUS progresses to the above malignancies remains still vague.

Long-term follow-up of patients with IgM-MGUS reveals that they are at increased risk for WM,3 a B-cell lymphoproliferative disorder (BLD) characterized by lymphoplasmacytic cell infiltration in bone marrow (BM) and the presence of IgM monoclonal gammopathy in the serum.4 Although the pathogenesis of WM has not been defined, familial clustering suggests that genetic factors may have a role in the development of the disease.5 Recently, Treon et al.6 revealed a novel recurring mutation (L265P) in the myeloid differentiation primary response 88 (MYD88) gene in patients with WM. Whole-genome sequencing, confirmed by Sanger sequencing, revealed that approximately 90% of patients with WM and 100% with non–IgM-secreting lymphoplasmacytic lymphoma (LPL) carried the mutation.6 On the contrary, MYD88-L265P was absent in the paired normal tissue of the above patients, as well as in 10 patients with MM (including two with IgM-MM), but it was expressed in 7% of patients with marginal-zone lymphoma. Interestingly, it was found that only 2 of 21 patients with IgM-MGUS (10%) were positive for MYD88-L265P using Sanger sequencing, while one of them developed WM.6 Subsequently, the same group, using an allele-specific PCR (AS-PCR) protocol applied in BM samples, detected the mutation in 93% of patients with WM and in 54% of patients with IgM-MGUS,7 while Landgren et al.8 detected the MYD88-L265P mutation in CD19+ BM cells of 5 out of 9 IgM-MGUS patients (56%), by Sanger sequencing. Additional studies confirmed that MYD88-L265P is a marker highly characteristic of WM, but it is also rarely present in other BLD, as splenic lymphoma with villous lymphocytes (SLVL).9, 10

To expand on this topic, a quick and reliable PCR-RFLP experimental protocol was generated to assess the status of MYD88-L265P expression in patients with WM and other LPDs. Twelve (12) patients with WM, 12 patients with B-cell chronic lymphocytic leukemia (CLL) and 8 with SLVL were enrolled in the study. Furthermore, consecutive samples of peripheral blood (PB) and BM isolated CD19+ cells, derived from a patient with monoclonal IgM-MGUS, were also analyzed for the presence of MYD88-L265P mutation. The diagnosis of the enrolled patients was based on standard diagnostic criteria,11 and all patients consented for their participation in the study according to Helsinki declaration.

Genomic DNA was extracted from BM and/or PB using the QIamp DNA blood mini kit (Qiagen, Valencia, CA, USA) and the detection of the L265P mutation was performed by PCR amplification of exon 5 of MYD88 gene, followed by restriction fragment length polymorphism (RFLP) analysis, as the presence of the mutation results in the generation of BsiEI restriction enzyme site. In particular, the forward and reverse primers, designed with the aid of the Oligo-6 software (NBI, Plymouth, MN, USA), were 5′-IndexTermCTGGCAAGAGAATGAGGGAATGT-3′, and 5′-IndexTermAGGAGGCAGGGCAGAAGTA-3′, respectively. For each PCR, a total of 100–200 ng of genomic DNA was amplified in a 30-μl reaction using 62.5 μM of each deoxynucleotide triphosphate, 20 pmol of each primer, 1.5 mM MgCl2 and 0.8 U Taq Polymerase (Bioron, Ludwigshafen, Germany) in a buffer supplied by the manufacturer. The PCR conditions were 2 min at 94 °C followed by 32 cycles of 94 °C for 30 s, 56 °C for 30 s, 72 °C for 30 s and 5 min at 72 °C after the last cycle. A 489 bp fragment was amplified by PCR and subjected to BsiEI digestion (New England Biolabs, Beverly, MA, USA) for 4 h at 37 °C. The mutated allele contains a BsiEI site resulting in 289 bp and 200 bp fragments, whereas the wild-type allele does not (Figure 1). All PCR and digestion procedures were carried out in the PCR engine apparatus PTC-200 (MJ Research, Watertown, MA, USA), and the PCR and digestion products were analyzed in 2% TBE (Tris-borate-EDTA) agarose gels. Additionally, PCR-RFLP results were confirmed by direct sequencing of purified CD19+ cells. The B-cell isolation was performed by magnetic sorting using the Easy Sep Kit on a Robosep instrument (STEMCELL Technologies Inc., Vancouver, Canada), resulting in a >90% B-cell purity (CD19+ cells). The CD19- fraction was used as the normal paired sample.

Figure 1
figure1

MYD88-L265P mutation established by PCR-digestion by BsiEI. (a) Serial dilutions of CD19+ cells of a patient with MW to identify the sensitivity of PCR-RFLP protocol. M: 100 bp DNA ladder (New England Biolabs). Lane 1: 100% CD19 cells; lane 2: 100% CD19+ cells; lane 3: 50% CD19+ cells; lane 4: 25% CD19+ cells; lane 5: 12.5% CD19+ cells; lane 6: 6.25% CD19+ cells; lane 7: 3.125 CD19+ cells; lane 8: 1.56% CD19+ cells. (b) Sequence chromatogram of MYD88-L265P mutation. The mutated nucleotide (c.794T>C) is indicated by a red arrow.

The MYD88-L265P mutation was detected in 11 out of 12 patients with WM (91.7%), in 1 out of 8 patients with SLVL (12.5%), while it was absent in all CLL patients. The sensitivity of PCR-RFLP was assessed by PCR analysis of samples obtained by serial dilutions of DNA of CD19+ cells of a WM patient in the DNA of CD19 cells, while the results were further verified by direct sequencing. Interestingly, PCR-RFLP protocol exhibited a greater sensitivity than direct sequencing, when applied to total BM cells (12.5 vs 25%). Moreover, the patient with IgM-MGUS carried the MYD88-L265P mutation in isolated CD19+ cells of both BM and PB in all consecutive samples and remained in a stable condition for the last 7 years.

The discovery of MYD88-L265P mutation seems to be a breakthrough in the evaluation of BLD, bearing in mind the difficulty of the diagnosis due to overlapping morphologic, immunophenotypic, cytogenetic and clinical features of these disorders.6, 11 In this study, we reported the presence of the MYD88-L265P mutation in 91.7% of patients with WM analyzed with PCR-RFLP. Similarly with previous studies, only 12.5% of our SLVL patients and none of the CLL samples carried the L265P mutation.9, 10 These findings further support the notion that MYD88-L265P mutation is probably a driver mutation which could give a competitive growth advantage to an early, possibly WM-bound, clone.6, 7 Therefore, the detection of the L265 mutation may be a useful tool in order to differentiate WM from other BLD. The described herein PCR-RFLP protocol is rapid and inexpensive, as it does not require special equipment, and its results can be obtained at the latest within 1–2 days. Moreover, it has a slightly increased sensitivity than direct sequencing when applied to total BM cells, possibly due to inherent problems of the fluorescence-based DNA sequencing.12, 13

It is interesting that we detected the MYD88-L265P mutation in a patient with IgM-MGUS, both in the isolated CD19+ cells of the BM and in the PB. The presence of the mutation, in the absence of disease progression for many years, suggests that this genetic defect alone may not be sufficient to sustain overt neoplastic disease.

In conclusion, this study presents a new method for the rapid and reliable detection of MYD88-L265P mutation in every day clinical practice, thus facilitating the validation of its possible diagnostic and prognostic value in patients with BLD.

References

  1. 1

    Marti GE, Rawstron AC, Ghia P, Hillmen P, Houlston RS, Kay N et al. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol 2005; 130: 325–332.

    Article  Google Scholar 

  2. 2

    Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346: 564–569.

    Article  Google Scholar 

  3. 3

    Kyle RA, Therneau TM, Rajkumar SV, Remstein ED, Offord JR, Larson DR et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003; 102: 3759–3764.

    CAS  Article  Google Scholar 

  4. 4

    Waldenstrom J . Incipient myelomatosis or ‘‘essential’’ hyperglobulinemia with fibrinogenopenia—a new syndrome? Acta Med Scand 1944; 117: 216–247.

    Article  Google Scholar 

  5. 5

    Kristinsson SY, Bjorkholm M, Goldin LR, McMaster ML, Turesson I, Landgren O . Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population based study in Sweden. Blood 2008; 112: 3052–3056.

    CAS  Article  Google Scholar 

  6. 6

    Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y et al. MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med 2012; 367: 826–833.

    CAS  Article  Google Scholar 

  7. 7

    Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X et al. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 2013; 121: 2051–2058.

    CAS  Article  Google Scholar 

  8. 8

    Landgren O, Staudt L . MYD88 L265P somatic mutation in IgM MGUS [letter]. N Engl J Med 2012; 367: 23.

    Article  Google Scholar 

  9. 9

    Jiménez C, Sebastián E, Del Carmen Chillón M, Giraldo P, Mariano Hernández J, Escalante F et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia. Leukemia 2013; 27: 1722–1728.

    Article  Google Scholar 

  10. 10

    Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S, Riboni R et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom’s macroglobulinemia and related lymphoid neoplasms. Blood 2013; 121: 2522–2528.

    CAS  Article  Google Scholar 

  11. 11

    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues 4th edn. IARC Press: Lyon, France, 2008; pp 194–195.

    Google Scholar 

  12. 12

    Leren TP, Rodningen OK, Rosby O, Solberg K, Berg K . Screening for point mutations by semi-automated DNA sequencing using sequenase and magnetic beads. Biotechniques 1993; 14: 618–623.

    CAS  Google Scholar 

  13. 13

    Zakeri H, Ampaaro G, Chen SM, Spurgeon S, Kwok PY . Peak height patterns in dichloro-rhodamine and energy transfer dye terminator sequencing. Biotechniques 1998; 25: 406–413.

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to M Speletas.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Argentou, N., Vassilopoulos, G., Ioannou, M. et al. Rapid detection of MYD88-L265P mutation by PCR-RFLP in B-cell lymphoproliferative disorders. Leukemia 28, 447–449 (2014). https://doi.org/10.1038/leu.2013.294

Download citation

Further reading

Search

Quick links